Curevac N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Curevac N V (CVAC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Curevac N V vs Its Competitors
- TTM: Trailing 12-month revenue of 579M vs 182,274M combined for its competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.0% annualized vs trailing 12 months), vs accelerating (+53.7%) for its tracked peer group.
- Growth: Curevac N V generated 895.5% revenue growth year over year in Q4 2024, vs 88.1% for its competitors combined.
- Profitability: Its -6.9% net margin compares with 2.3% for the peer group.
- Peer revenue share: Curevac N V accounted for 0.9% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $1.57M compares with $1.26M for the peer group (1.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CVAC Sales vs. its Competitors, Q4 2024
Curevac N V reported revenue growth of 895.54 % year on year in Q4 2024, above its competitors' combined revenue growth of 88.05 %.
With a net margin of -6.88 %, Curevac N V reported lower profitability than its competitors (2.33 %).
Curevac N V generated 0.85 % of the combined sales of its peer group, up from 0.16 % a year earlier.
API endpoints for this dataset
Curevac N V vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Curevac N V reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Curevac N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Curevac N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Curevac N V's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 895.5% for Curevac N V. Curevac N V's share of combined industry revenue moved from 0.01% to 0.11%, a gain of 0.10 percentage points.
Curevac N V's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Curevac N v | Yes | Yes | Yes | No |
| Competitors combined (71) | ||||
| High-Confidence Competitors (4) | ||||
| Similar Growth & Profitability (8) | 50.00 % (4 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CVAC Stock Performance relative to its Competitors
CVAC Stock Performance relative to High-Confidence Competitors
CVAC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Tourmaline Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Curevac N V's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Curevac N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Curevac N v |
1,049.76 | 579.06 |
 Gsk Plc |
207,208.61 | 43,093.89 |
 Pfizer Inc |
169,021.89 | 63,625.00 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Moderna Inc |
101,167.62 | 2,228.00 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
| SUBTOTAL | 783,494.98 | 182,983.63 |
Sign in to see all competitors of Curevac N v .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Curevac N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Curevac N V's Competitors Named by the Company
Competitive relationships identified from Curevac N V reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pfizer | Company report | 85% |
| BioNTech | Company report | 85% |
| Frame Cancer Therapeutics | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Vaxart Inc | Company report | 85% |
| Arcturus Therapeutics Holdings Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Curevac N V's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Curevac N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Emergent Biosolutions Inc | MCM Products 54.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Curevac N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Curevac N v | 1,050 | 1,565,039 | 474,284 |
| Gsk Plc | 207,209 | 169,660,977 | 32,662,867 |
| Pfizer Inc | 169,022 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Moderna Inc | 101,168 | 474,043 | -670,426 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| PEERS TOTAL | 782,445 | 1,264,240 | 110,018 |
Curevac N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | IE 27.07 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Curevac N V's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Curevac N V's industry classification, broader than the peer set above. Market cap in millions of $.Curevac N V ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Curevac N v | 1,176 | 0.00 % |
Market cap and industry share for the rest of Curevac N V's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-01-05.
Curevac N V's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.04 % | 37.89 % (avg) | +45.2 pp |
| Operating Margin | 33.20 % | industry median | +73.2 pp |
| EBITDA Margin | 35.67 % | -6.23 % (avg) | +41.9 pp |
| Capital Intensity (Capex / Revenue) | 2.67 % | 7.58 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Curevac N V's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 4.0x | 26.6x | -22.6x |
| EV / EBITDA | 0.7x | 15.9x | -15.2x |
| P/B | 0.9x | 4.3x | -3.4x |
| Return on Equity | 24.34 % | industry aggregate | 10.13 % |
| Return on Invested Capital | 12.20 % | -9.83 % (avg) | 22.03 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Curevac N V's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue Growth | 27.36 % | -18.13 % | 500.00 % |
| Operating Margin | - | - | 33.20 % |
| Return on Invested Capital | -17.48 % | -20.35 % | 12.20 % |
| P/E | - | - | 4.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Curevac N V's Strategic Group Map
Curevac N V is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Curevac N V's trailing-12-month revenue growth of 500.0% and operating margin of 33.2% compares with an average of 426.7% growth and -1.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Curevac N V sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Curevac N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.67 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Curevac N V's dedicated Suppliers and Customers pages, not here.
Curevac N V's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Curevac N V falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Curevac N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 73.2 points above the industry median.
- Return on equity 10.1 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+314.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- Trades at a lower P/E than the industry average (4.0x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (61.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Curevac N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Curevac N v | 6.66 | 7.28 | - |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Curevac N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Curevac N v | Q4 2024 | +895.8 % | - |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | +7.1 % | +50.2 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Curevac N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Curevac N v | Q4 2024 | +31.2 % | -72.6 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Curevac N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Curevac N v | 21.12% | 20.52% | 24.34% |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Moderna Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Curevac N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Curevac N v | 6.47 | 1.81 |
| Gsk Plc | 36.26 | 4.81 |
| Pfizer Inc | 41.83 | 2.66 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Moderna Inc | - | 45.41 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| PEERS AVERAGE | 48.82 | 4.28 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.